ZakAria is a humanized monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.ZakAria® (Pembrolizumab) is used alone or in combination with other medicines to treat certain types of cancer including:
Skin cancer (Melanoma and Merkel cell carcinoma);
Lung cancer;
Head and neck cancer;
Certain types of lymphoma (Hodgkin and large B-cell)
Cancer of the kidney, bladder, and urinary tract;
Colorectal cancer;
Liver cancer;
Breast cancer;
Cancer of the cervix or uterus;
Advanced stomach or esophageal cancer;
